What are Antibody-Drug Conjugates (ADCs) and how do they work in cancer treatment?
What are the three main components of an ADC?
What are the current ADC drugs in Phase 3 clinical trials and for what cancers are they used?
How effective are ADCs in terms of progression-free survival and complete response rates?
What limitations and side effects are associated with ADCs?
What are the future research avenues, like gene editing, nanotechnology, and immunotherapy, in overcoming ADC limitations?
Important Highlights:
Antibody-Drug Conjugates (ADCs) are specialized cancer treatments that combine an antibody with a cytotoxic drug to target cancer cells.
ADCs consist of three main components: an antibody, a cytotoxic drug, and a chemical linker.
Patritumab Deruxtecan is an FDA-approved ADC primarily used for gastric and non-small cell lung cancers, with an effectiveness of around 9 months for progression-free survival.
Ifentimab Deruxtecan shows a 61% response rate in treating multiple myeloma and is in Phase 3 clinical trials.
Resistance to ADCs often occurs when cancer cells stop expressing the targeted antigen.
Future research in gene editing, nanotechnology, and immunotherapy aims to overcome limitations and improve the efficacy of ADCs.

свернуть